Pancreatic and Thyroid Cancer: Januvia, Byetta, Janumet, Victoza, Bydureon

Over 350 million patients worldwide suffer from Type 2 Diabetes Mellitus. Type 2 Diabetes is the most common form of diabetes and is the most frequent cause of blindness, amputations, and dialysis worldwide. It truly is one of the major health challenges of the 21st century. Incretins, including Januvia, Janumet, Byetta, Victoza, and others, were designed to prevent these diabetic complications. However, the use of Incretins has been associated with a significant risk of developing pancreatic cancer and thyroid cancer. If you or a loved one has used or is using an Incretin, read on for facts about these drugs and the litigation surrounding them.

Facts about Incretins:

  • Januvia, manufactured by Merck, was first approved by the FDA in 2006 to help diabetes patients improve glycemic control. In 2007, the FDA approved Merck’s successor to Januvia, Janumet. Since that time, Januvia has become the most successful drug to be launched since 2006. In 2012, global sales of Januvia reached $5.7 billion.
  • Byetta, manufactured by both Amylin Pharmaceuticals and Eli Lilly, was first approved by the FDA in 2005 to help prevent diabetic complications. Worldwide sales of Byetta are predicted to reach $1.00 billion by 2015.
  • In as early as February, 2010, publications noted concerns over a linkage between the use of Incretins and the development of pancreatic cancer. Researchers warned that individuals treated with Incretins could develop pancreatic cancer. In February, 2011, a journal article was published regarding the link between Incretins and the development of both pancreatic and thyroid cancers. This research was based off of FDA Adverse Event Reports and reported that the event rate for pancreatic cancer was 2.9-fold greater and for thyroid cancer was 4.73-fold greater in patients treated with Byetta compared to other therapies. Pancreatic cancer is an aggressive and deadly cancer, affording patients just a 1.8% chance of survival for longer than five years after the cancer spreads.
  • Lawsuits alleging that the Incretin manufacturers failed to adequately warn about the increased risks of developing both pancreatic cancer and thyroid cancer from using their drugs. In addition, the risks posed by these drugs severely outweigh any benefit received from ingesting them. Rather than responding to the serious risks posed by their products, the Incretin manufacturers continued to place Americans at risk of developing deadly cancers by putting profits over safety.

Litigation News:

  • Numerous lawsuits have been filed in the Southern District of California and other districts alleging injuries as a result of Incretin ingestion.
  • On August 26, 2013, the Judicial Panel on Multidistrict Litigation (JPMDL) granted a petition filed by both parties and created a Multidistrict Litigation (MDL) in the Southern District of California.
  • On October 17, 2013, the first Status Conference was held in the litigation during which significant dates and deadlines were set.
  • On October 21, 2013, Judge Anthony Battaglia appointed Johnson Becker Partner Michael Johnson to the Plaintiffs’ Executive Committee, earning the firm the honor and responsibility of being one of the lead law firms in this national litigation.

If you or a loved one has used or is using an Incretin and have suffered from pancreatic cancer or thyroid cancer, or you have lost a loved one for one of these reasons, find out how Johnson Becker, PLLC can help you. Please either call us at our toll free number (800) 279-6386 or fill out our case review form here on our website and submit it for a free consultation.